Alembic API-III Inspection Report 2025

  Published 11 months ago

Alembic Pharmaceuticals' API-III facility inspection occurred March 17-21, 2025. The company produces globally approved generic drugs with USFDA certified research and manufacturing.

  • Inspection timeframe: 5-day review of operations and compliance standards.
  • Vertically integrated R&D and manufacturing ensure product quality and regulatory adherence.
  • Facility approved by USFDA and other global regulators for pharmaceutical production.

You might like these

OIL, IREL Join Forces on Critical Minerals

India's 50 GW Green Power Stuck

Eternal Falls as Jefferies Warns of MSCI Weight Cut Risk

Wipro & Entrust: Accelerating Secure Identity Solutions

Shriram Finance: Motilal Oswal Raises Price Target

Bajel Projects Stock Surges 5% on Mega Power Order

IndusInd Bank Shares Surge After RBI Comments

News that matters the most ⚡